LeMaitre Vascular, Inc. $LMAT Stock Holdings Reduced by Squarepoint Ops LLC

Squarepoint Ops LLC reduced its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 52.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,768 shares of the medical instruments supplier’s stock after selling 28,394 shares during the period. Squarepoint Ops LLC’s holdings in LeMaitre Vascular were worth $2,473,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in LMAT. Sound Income Strategies LLC lifted its holdings in shares of LeMaitre Vascular by 425.6% during the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 183 shares during the last quarter. Catalyst Capital Advisors LLC acquired a new position in LeMaitre Vascular in the first quarter worth approximately $32,000. Nykredit A S bought a new position in LeMaitre Vascular during the second quarter valued at approximately $82,000. Northwestern Mutual Wealth Management Co. bought a new position in LeMaitre Vascular during the second quarter valued at approximately $102,000. Finally, EverSource Wealth Advisors LLC lifted its stake in LeMaitre Vascular by 28.4% in the first quarter. EverSource Wealth Advisors LLC now owns 1,393 shares of the medical instruments supplier’s stock valued at $152,000 after acquiring an additional 308 shares during the last quarter. 84.64% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $80.77 on Tuesday. The stock has a 50-day simple moving average of $89.48 and a 200 day simple moving average of $98.71. LeMaitre Vascular, Inc. has a twelve month low of $78.27 and a twelve month high of $118.01. The stock has a market capitalization of $1.85 billion, a PE ratio of 28.34, a P/E/G ratio of 2.33 and a beta of 0.50. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business had revenue of $70.38 million during the quarter, compared to analyst estimates of $71.47 million. During the same period last year, the business earned $0.60 EPS. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. Research analysts anticipate that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Thursday, August 20th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Thursday, August 20th. This represents a $1.00 dividend on an annualized basis and a yield of 1.2%. LeMaitre Vascular’s payout ratio is 35.09%.

Wall Street Analyst Weigh In

LMAT has been the subject of several recent research reports. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, August 1st. Barrington Research downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Citigroup reaffirmed a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Wells Fargo & Company decreased their price objective on shares of LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a report on Wednesday, August 5th. Finally, Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $110.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures and markets medical devices used primarily in the treatment of peripheral vascular disease. Its products are designed for vascular surgeons and other specialists performing procedures on arteries and veins outside the heart and brain.

The company’s portfolio includes biologic and synthetic vascular grafts, thrombectomy catheters, angioplasty balloons, valvulotomes, vascular shunts, vessel-closure devices and other surgical instruments. LeMaitre also offers products used in vessel preparation, plaque removal and the repair or replacement of diseased blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular serves customers in the United States and international markets.